Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) announced on February 10, 2026 the grant of 40,200 restricted stock units (RSUs) to 11 newly hired employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest 25% at one year, with the remaining 75% vesting in twelve equal quarterly installments, subject to continued employment and plan terms.
Details
News Market Reaction – ESPR
On Feb 12, the first trading day after this news, ESPR closed 1.73% below the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Inducement RSUs granted
- 40,200 RSUs
- Granted to 11 new employees on February 10, 2026
- New employees
- 11 employees
- Recipients of inducement RSU awards
- Initial vesting portion
- 25 percent
- Vests on one-year anniversary of vesting commencement date
- Remaining vesting portion
- 75 percent
- Vests in twelve equal quarterly installments after first anniversary
- Quarterly installments
- 12 installments
- For remaining 75 percent of RSUs after first anniversary
- Marketed therapies
- 2 therapies
- Oral, once-daily, non-statin LDL-C therapies currently marketed
- Countries with approvals
- more than 40 countries
- Global approvals for Esperion’s LDL-C therapies
Historical Context
-
Preliminary 2025 results and long-term Vision 2040 growth strategy.
-
Announcement of presentation at J.P. Morgan Healthcare Conference.
-
ACC statement recommending bempedoic acid for PAD with diabetes.
-
Inducement stock options and RSUs under 2017 plan including CCO grant.
-
Partner Otsuka’s launch of NEXLETOL in Japan with milestone payment.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
rsus financial
nasdaq listing rule 5635(c)(4) regulatory
equity incentive plan financial
low-density lipoprotein cholesterol (ldl-c) medical
primary sclerosing cholangitis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.